Except for lower levels of 11β-OH-3α,5α-THA in patients, the levels of the remaining six 11β-hydroxy-androstanes were unaltered, which may indicate unaltered functioning of CYP11B1 in MS patients. This evidence concerns the gene CYP11B1 and myeloid sarcoma.